AG2R LA Mondiale Gestion D Actifs Buys 348 Shares of Regeneron Pharmaceuticals, Inc. $REGN

AG2R LA Mondiale Gestion D Actifs increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,453 shares of the biopharmaceutical company’s stock after buying an additional 348 shares during the period. AG2R LA Mondiale Gestion D Actifs’ holdings in Regeneron Pharmaceuticals were worth $2,338,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Activest Wealth Management raised its stake in Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 21 shares in the last quarter. Costello Asset Management INC bought a new position in Regeneron Pharmaceuticals in the first quarter worth about $27,000. Saudi Central Bank purchased a new stake in Regeneron Pharmaceuticals in the first quarter worth about $27,000. Colonial Trust Advisors purchased a new stake in Regeneron Pharmaceuticals in the first quarter worth about $32,000. Finally, SouthState Corp grew its holdings in Regeneron Pharmaceuticals by 550.0% in the first quarter. SouthState Corp now owns 52 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 44 shares during the period. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Trading Up 0.4%

NASDAQ:REGN opened at $577.95 on Friday. The company’s 50 day moving average price is $576.32 and its 200-day moving average price is $562.62. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $943.83. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The stock has a market cap of $61.26 billion, a price-to-earnings ratio of 14.57, a PEG ratio of 1.80 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3.68 billion for the quarter, compared to analysts’ expectations of $3.30 billion. During the same quarter in the prior year, the company posted $11.56 earnings per share. The business’s revenue for the quarter was up 3.6% on a year-over-year basis. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were issued a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.87%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on REGN shares. Truist Financial cut their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Morgan Stanley cut their price objective on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. Rothschild & Co Redburn started coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, August 14th. They issued a “buy” rating and a $890.00 price objective on the stock. Jefferies Financial Group upped their price objective on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a report on Wednesday, August 27th. Finally, Argus cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, June 30th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $802.35.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.